FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.